A serum-free protocol for the ex vivo expansion of Cytokine-Induced Killer cells using gas-permeable static culture flasks.
Cell Culture Techniques
/ instrumentation
Cell Death
/ drug effects
Cell Differentiation
Cell Line, Tumor
Cell Proliferation
Cell Survival
/ drug effects
Culture Media, Serum-Free
/ pharmacology
Cytokine-Induced Killer Cells
/ cytology
Cytotoxicity, Immunologic
/ drug effects
Gases
/ chemistry
Humans
Immunologic Memory
/ drug effects
Permeability
Phenotype
Adoptive cell therapy
Cytokine-Induced Killer cells
Immunotherapy
Serum-free
ex vivo expansion
Journal
Cytotherapy
ISSN: 1477-2566
Titre abrégé: Cytotherapy
Pays: England
ID NLM: 100895309
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
06
11
2019
revised:
13
04
2020
accepted:
06
05
2020
pubmed:
8
7
2020
medline:
20
2
2021
entrez:
8
7
2020
Statut:
ppublish
Résumé
Cytokine-Induced (CIK) cells represent an attractive approach for cell-based immunotherapy, as they show several advantages compared with other strategies. Here we describe an original serum-free protocol for CIK cell expansion that employs G-Rex devices and compare the resulting growth, viability, phenotypic profile and cytotoxic activity with conventional culture in tissue flasks. CIK cells were obtained from buffy coats, seeded in parallel in G-Rex and tissue flasks, and stimulated with clinical-grade IFN-γ, anti-CD3 antibody and IL-2. G-Rex led to large numbers of CIK cells, with a minimal need for technical interventions, thus reducing the time and costs of culture manipulation. CIK cells generated in G-Rex showed a less differentiated phenotype, with a significantly higher expression of naive-associated markers such as CD62L, CD45RA and CCR7, which correlates with a remarkable expansion potential in culture and could lead to longer persistence and a more sustained anti-tumor response in vivo. The described procedure can be easily translated to large-scale production under Good Manufacturing Practice. Overall, this protocol has strong advantages over existing procedures, as it allows easier, time-saving and cost-effective production of CIK effector cells, fostering their clinical application.
Identifiants
pubmed: 32631696
pii: S1465-3249(20)30680-0
doi: 10.1016/j.jcyt.2020.05.003
pii:
doi:
Substances chimiques
Culture Media, Serum-Free
0
Gases
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
511-518Informations de copyright
Copyright © 2020 International Society for Cell and Gene Therapy. Published by Elsevier Inc. All rights reserved.